Skip to main content

Advertisement

SpringerLink
Log in

Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines

  • Review
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Vaccines against human papillomavirus (HPV), the primary causative agent in cervical cancer, are licensed. This paper contains the Central European Vaccination Advisory Group (CEVAG) guidance statement on the introduction of HPV vaccines in central Europe. Eight countries currently have medical representatives on CEVAG: the Czech Republic, Estonia, Hungary, Lithuania, Poland, Romania, Slovakia and Turkey. By raising awareness and disseminating information, CEVAG aims to promote the efficient and safe use of vaccines to prevent, control and if possible eliminate infectious diseases. In January 2008, the European Centre for Disease Prevention and Control published a report entitled Guidance for the Introduction of HPV Vaccines in EU Countries. Members of CEVAG have taken the information relevant to their countries from this report and, with consideration of local issues, produced these guidance recommendations for the introduction of HPV vaccines in the CEVAG region, which may be adapted for use in individual countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Arbyn M, Raifu AO, Autier P et al (2007) Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 18:1708–1715

    Article  PubMed  CAS  Google Scholar 

  2. Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861–1868

    Article  PubMed  CAS  Google Scholar 

  3. Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32(Suppl 1):S16–24

    Article  PubMed  Google Scholar 

  4. Bjorge T, Engeland A, Luostarinen T et al (2002) Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 87:61–64

    Article  PubMed  CAS  Google Scholar 

  5. Bosch FX, Lorincz A, Munoz N et al (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244–265

    PubMed  CAS  Google Scholar 

  6. Bray F, Loos AH, McCarron P et al (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 14:677–686

    Article  PubMed  Google Scholar 

  7. Brown D (2007) First analysis of cross protection against persistent infection, cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. 47th Interscience Conference on Animicrobial Agents and Chemotherapy

  8. Copenhagen: National Board of Health, DCfHTa. (2007). “National Board of Health Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV).” A health technology assessment, from http:/www.sst.dk/publ/Publi2007/MTV/HPV/HPV_vacciationsmfatn_en.pdf

  9. ECDC (2008) Guidance for the introduction of HPV vaccines in EU countries. From http://ecdc.europa.eu/pdf/HPVreport.pdf

  10. Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13:28–41

    Article  PubMed  Google Scholar 

  11. Ferlay J, Bray F, Pisani P et al (2004) GLOBOCAN 2002: Cancer Incidence mortality and prevalence worldwide. IARC CancerBase No 5

  12. Gall S, Teixeira J, Wheeler C et al (2007) Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1VLP AS04 candidate vaccine. AACR, Philadelphia

    Google Scholar 

  13. Ghaemmaghami F, Nazari Z, Mehrdad N (2007) Female genital warts. Asian Pac J Cancer Prev 8:339–347

    PubMed  Google Scholar 

  14. Goldie SJ, Kim JJ, Kobus K et al (2007) Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25:6257–6270

    Article  PubMed  Google Scholar 

  15. Harper D, Gall S, Naud P et al (2008) Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated wit Cervarix™ (GSK's HPV 16/18 ASO4 candidate vaccine). 39th Annual Meeting of the Society of Gynecologic Oncologists, Gynecologic Oncology

  16. Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765

    Article  PubMed  CAS  Google Scholar 

  17. Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247–1255

    Article  PubMed  CAS  Google Scholar 

  18. Kulasingam SL, Myers ER (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290:781–789

    Article  PubMed  Google Scholar 

  19. Manhart LE, Koutsky LA (2002) Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29:725–735

    Article  PubMed  Google Scholar 

  20. Munoz N, Bosch FX, de Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527

    Article  PubMed  Google Scholar 

  21. Munoz N, Bosch FX, de Sanjose S et al (1992) The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 52:743–749

    Article  PubMed  CAS  Google Scholar 

  22. Olsson SE, Villa LL, Costa RL et al (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931–4939

    Article  PubMed  CAS  Google Scholar 

  23. Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170

    Article  PubMed  CAS  Google Scholar 

  24. Picconi MA, Eijan AM, Distefano AL et al (2000) Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes. J Med Virol 61:65–69

    Article  PubMed  CAS  Google Scholar 

  25. Sanders GD, Taira AV (2003) Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9:37–48

    PubMed  Google Scholar 

  26. Santegoets LA, Seters M, Helmerhorst TJ et al (2007) HPV related VIN: highly proliferative and diminished responsiveness to extracellular signals. Int J Cancer 121:759–766

    Article  PubMed  CAS  Google Scholar 

  27. Schiffman M, Castle PE, Jeronimo J et al (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907

    Article  PubMed  CAS  Google Scholar 

  28. Schwarz TF, Descamps D, for the HPV Vaccine Study Group for Adult Women (2007) Immune response in women up to 55 years of age vaccinated with CervarixTM the HPV-16/18 L1 VLP AS04 vaccine candidate. EUROGIN, Paris

    Google Scholar 

  29. Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632

    Article  PubMed  CAS  Google Scholar 

  30. Srodon M, Stoler MH, Baber GB et al (2006) The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 30:1513–1518

    Article  PubMed  Google Scholar 

  31. Stanley M (2007) Prophylactic HPV vaccines. J Clin Pathol 60:961–965

    Article  PubMed  Google Scholar 

  32. Steben M, Duarte-Franco E (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107:S2–S5

    Article  PubMed  CAS  Google Scholar 

  33. Tachezy R, Hamsikova E, Hajek T et al (1999) Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 58:378–386

    Article  PubMed  CAS  Google Scholar 

  34. Tong SY, Lee YS, Park JS et al (2007) Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix. Int J Gynecol Cancer 17:1307–1313

    Article  PubMed  CAS  Google Scholar 

  35. Tornesello ML, Duraturo ML, Losito S et al (2008) Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer 122:132–137

    Article  PubMed  CAS  Google Scholar 

  36. Villa LL, Costa RL, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459–1466

    Article  PubMed  CAS  Google Scholar 

  37. Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19

    Article  PubMed  CAS  Google Scholar 

  38. Wheeler C, Teixeira J, Romanowski B (2008) High and sustained HPV 16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix (GSK HPV-16/18 ASO4 vaccine). Abstract at ESPID's Annual Meeting, Graz, Austria

  39. Winer RL, Hughes JP, Feng Q et al (2006) Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354:2645–2654

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Preparation of this report was supported by an educational grant from GlaxoSmithKline (GSK). Editorial support was provided by Dr Debra Scates of Wells Healthcare on behalf of GSK. All authors were actively involved in the selection and review of all content and had full editorial control during the writing of the manuscript.

Conflict of interest

The authors Mustafa Bakir, Hanna Czajka, Irja Lutsar, Zsófia Mészner and Nuran Salman declare that they have no conflict of interest. Roman Prymula has received consulting fees in the last 3 years and honoraria or travel grants from GlaxoSmithKline (GSK) and Merck Sharp & Dohme (MSD). Ioana Anca has received travel grants from GSK and Wyeth and lecture fees from Wyeth. Pavol Šimurka has received consulting fees, lecture fees and grant support from Wyeth and consulting fees and lecture fees from GSK and MSD. Vytautas Usonis has been the principal investigator in studies supported by GSK, Novartis and Wyeth-Lederle Vaccines; he has been a scientific consultant to Aventis Pasteur, Baxter, GSK, Merck and Wyeth-Lederle Vaccines and has received sponsorship from these companies to attend scientific meetings. Francis André has previously been an employee of a vaccine manufacturer but is now retired and currently has no conflict of interest.

Author information

Authors and Affiliations

  1. Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic

    Roman Prymula

  2. Department of Pediatrics “Prof. Dr. Alfred Rusescu”—Institute for Mother and Child Care, University of Medicine and Pharmacy, Bucharest, Romania

    Ioana Anca

  3. Rue du Moulin 23, 1330, Rixensart, Belgium

    Francis André

  4. Department of Pediatrics, Division of Pediatric Infectious Diseases, Marmara University School of Medicine, Istanbul, Turkey

    Mustafa Bakir

  5. Vaccination Centre, Krakow Specialist Hospital, Krakow, Poland

    Hanna Czajka

  6. Department of Microbiology, Faculty of Medicine, University of Tartu, Tartu, Estonia

    Irja Lutsar

  7. National Institute of Child Health, Budapest, Hungary

    Zsófia Mészner

  8. Division of Infectious Disease and Clinical Microbiology at the University, Istanbul, Turkey

    Nuran Salman

  9. Department of Pediatrics, University Hospital, Trencin, Slovakia

    Pavol Šimurka

  10. Vilnius University Centre of Paediatrics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

    Vytautas Usonis

Authors
  1. Roman Prymula
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ioana Anca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francis André
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Bakir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hanna Czajka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Irja Lutsar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zsófia Mészner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nuran Salman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pavol Šimurka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vytautas Usonis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roman Prymula.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prymula, R., Anca, I., André, F. et al. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. Eur J Pediatr 168, 1031–1035 (2009). https://doi.org/10.1007/s00431-009-0972-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-009-0972-6

Keywords

Search

Navigation